Here, we report a case of paediatric ␤-thalassaemia Patients with autoimmune haemolytic anaemia (AIHA) after allogeneic transplantation are usually treated with either steroids alone or multiple immunosuppressive therapies, including antithymocyte globulin, cyclophosphamide, immunoglobulin, splenectomy, vincristine and erythropoietin. The overall response to these therapies has been generally unsatisfactory.
Patients with autoimmune haemolytic anaemia (AIHA) after allogeneic transplantation are usually treated with either steroids alone or multiple immunosuppressive therapies, including antithymocyte globulin, cyclophosphamide, immunoglobulin, splenectomy, vincristine and erythropoietin. The overall response to these therapies has been generally unsatisfactory. 1 Quartier et al 2 described the treatment of childhood refractory AIHA with rituximab. Therefore, we would like to report our experience about a successful treatment of refractory AIHA in a post-unrelated allogeneic bone marrow transplant pediatric patient with rituximab.
Rituximab therapy for refractory AIHA post unrelated BMT
A 37-month-old Thai boy who had ␤-thalaessaemia major underwent unrelated T cell-nondepleted bone marrow transplantation. His course of transplant was uneventful with full donor engraftment. On day 180 post transplant, the child was hospitalized due to immediate onset of pallor and listlessness. Physical examination was unremarkable with the exception of pallor and jaundice. The child did not present either spleen or liver enlargement. Full blood count at admission showed haemoglobin 6.7 g/dl, with reticulocyte count 35 × 10 9 /l and normal white blood cell and platelet counts. Total and unconjugated bilirubin levels were increased (2.4 mg/dl and 1.6 mg/dl, respectively), lactate dehydrogenase (LDH) was 400 U/l. Direct and indirect Coombs tests were positive (direct Coombs test: ++++, indirect Coombs test: +). Antibody identification was anti-E (IgG) and cold autoantibody (IgM). Evaluation of the blood film revealed the presence of spherocytes and autoagglutination. A blood count performed 1 week earlier had shown normal haemoglobin (10 g/dl). Bone marrow aspiration showed erythroid hyperplasia. Then, the child was treated with methylprednisolone (2 mg/kg per day) and intravenous immunoglobulin (2 gm/kg). Due to steadily decreasing haemoglobin level on day 3 of admission ( Figure 1 ), the child was transfused and the dose of methylprednisolone was increased to 5 mg/kg per day. During the first week of admission, his haemoglobin levels were unsteady, reticulocyte count was increased to 220 × 10 9 /l, and serum unconjugated bilirubin was increased to Bone Marrow Transplantation 5.6 mg/dl. Although the child was transfused twice more to maintain haemoglobin level above 5 g/dl as shown in Figure 1 , he remained listless. Since the overall response to conventional therapies has been generally unsatisfactory in AIHA post-transplant patients as this child was, 1 the recent introduction of new immunomodulating agents such as monoclonal antibodies represents an appealing and promising treatment modality for patients with this most severe and/or refractory form of such disease. 3 In refractory or chronic disease, use of rituximab (anti-CD20 monoclonal antibody) is attractive because it could reduce or avoid some side-effects of prolonged therapy with corticosteroids and/or other aspecific immunosuppressive drugs. We decided to give him rituximab 375 mg/m 2 as a 4-h infusion, once weekly for a total of two doses. The drug was well tolerated and the child did not present any adverse reaction or side-effects. Haemolysis was noted to be decreased during 3 months of observation after treatment (haemoglobin 10 g/dl, reticulocyte count 40 × 10 9 /l, unconjugated bilirubin 0.6 mg/dl, LDH 250 U/l). The percentage of CD19 + and CD20
+ cells had dropped from the pretreatment values of 23.5% and 6.4%, respectively, to values less than 1% for both antigens 2 weeks after second infusion. The corticosteroid for this child was tapered off and discontinued in 1 month after the second infusion. Since recovery of B lymphocytes after treatment with rituximab had been described to start from 6 to 9 months after the last administration, we gave replacement therapy with IVIG. 4 During the observation period, the child did not develop any significant infectious complication. In Zecca et al's 5 and our own experience, good response to rituximab infusion occurred after only two doses, and it was sustained, allowing discontinuation of all other immunosuppressive therapies. We suggest that two doses of rituximab might be sufficient, thus saving cost. In conclusion, even though a longer follow-up is required to assess the long-term efficacy of this treatment, our case provides a basis for future prospective trials aimed at defining the role of rituximab for antibodymediated haematologic disorders especially in the poststem cell transplant setting.
